Core Viewpoint - The Hong Kong stock market experienced a significant drop due to external market influences, but the innovative drug sector rebounded quickly, indicating strong investor interest and potential growth opportunities in this area [1] Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) opened low but rapidly turned positive, with notable gains in constituent stocks such as Jiage Ankang-B rising over 4% and Baijie Shenzhou and Kangnuo Ya-B each increasing over 1% [1] - As of 9:55 AM, the innovative drug ETF (159567) saw a net subscription of 110 million shares, reflecting strong demand [1] - The ETF has recorded net inflows for four consecutive trading days, accumulating over 900 million yuan, with total shares surpassing 9.2 billion, setting a new record [1] Group 2: Industry Developments - The biotechnology sector in China has recently seen positive developments, with 35 research projects from various innovative drug companies selected for oral presentations at the ESMO 2025 conference, marking a record achievement [1] - Significant collaborations, such as the partnership between Innovent Biologics and Takeda, valued at 11.4 billion USD, highlight global recognition of the value of Chinese innovative drugs [1] Group 3: Investment Focus - Analysts suggest that the focus of the innovative drug market is shifting from broad valuation recovery to the fundamental performance capabilities of companies [1] - Companies with exceptional clinical data, strong commercialization capabilities, and successful international expansion potential are likely to emerge as future winners in the sector [1]